Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reversible hepatic dysfunction in association with cyclophosphamide therapy

D V Milford1, N Butler, R Clarke

  • 1Department of Nephrology, Children's Hospital, Birmingham, UK.

European Journal of Pediatrics
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effect of child home safety training upon three family support practitioner groups: a mixed-methods study.

Perspectives in public health·2023
Same author

Stabilized Radiation Pressure Acceleration and Neutron Generation in Ultrathin Deuterated Foils.

Physical review letters·2022
Same author

Absolute calibration of Fujifilm BAS-TR image plate response to laser driven protons up to 40 MeV.

The Review of scientific instruments·2022
Same author

Increased incidence of idiopathic paediatric facial palsy during the coronavirus disease 2019 pandemic.

The Journal of laryngology and otology·2021
Same author

Detection of asymptomatic carotid stenosis in patients with lower-extremity arterial disease: development and external validations of a risk score.

The British journal of surgery·2021
Same author

The Scattered Light Time-history Diagnostic suite at the National Ignition Facility.

The Review of scientific instruments·2021

Cyclophosphamide treatment for nephrotic syndrome in a child led to reversible jaundice and abnormal liver function. Pediatricians should monitor for potential drug-induced liver injury in children receiving this therapy.

Area of Science:

  • Pediatric Nephrology
  • Clinical Pharmacology
  • Hepatology

Background:

  • Nephrotic syndrome is a kidney disorder often treated with immunosuppressive agents.
  • Cyclophosphamide is an alkylating agent used in treating various conditions, including nephrotic syndrome.
  • Drug-induced liver injury (DILI) is a significant concern in pediatric pharmacotherapy.

Observation:

  • A 5.5-year-old child with nephrotic syndrome received cyclophosphamide therapy.
  • After nine weeks, the child presented with jaundice and elevated liver function tests.
  • No infectious cause for the liver abnormalities was identified.

Findings:

  • Cyclophosphamide therapy was associated with transient, reversible hepatic dysfunction in this pediatric patient.
  • Liver function tests normalized within five weeks of discontinuing cyclophosphamide.

Related Experiment Videos

  • This case highlights a rare adverse effect of cyclophosphamide in children with nephrotic syndrome.

    • Implications:

    • Pediatricians should consider cyclophosphamide as a potential cause of liver dysfunction in children with nephrotic syndrome.
    • Awareness of this potential side effect is crucial for prompt diagnosis and management.
    • Further surveillance for hepatic adverse events may be warranted in pediatric patients on cyclophosphamide.